Metastatic neuroblastoma in infants: are survival rates excellent only within the stringent framework of clinical trials?

Fecha de publicación: 01/01/2017

Autores de IIS La Fe

Julia Balaguer Guill

Autor
Vanessa Segura Caballer

Autor
Victoria Castel Sánchez

Autor
Adela Cañete Nieto

Autor

Participantes ajenos a IIS La Fe

Di Cataldo, A
Agodi, A
Garaventa, A
Barchitta, M
Bianchi, M
Castellano, A
Cesaro, S
Couselo, JM
Cruz, O
D'Angelo, P
De Bernardi, B
Donat, J
de Andoin, NG
Hernandez, MI
La Spina, M
Lillo, M
Lopez-Almaraz, R
Luksch, R
Mastrangelo, S
Mateos, E
Molina, J
Moscheo, C
Mura, R
Porta, F
Russo, G
Tondo, A
Torrent, M
Vetrella, S
Villegas, JA
Viscardi, E
Zanazzo, GA

Grupos

Investigación Clínica y Traslacional en Cáncer

Leader

José Gómez Codina

Abstract

SIOPEN INES protocol yielded excellent 5-year survival rates for MYCN-non-amplified metastatic neuroblastoma. Patients deemed ineligible due to lack or delay of MYCN status or late registration were treated, but not included in the study. Our goal was to analyse survival at 10 years among the whole population. Italian and Spanish metastatic INES patients' data are reported. SPSS 20.0 was used for statistical analysis. Among 98 infants, 27 had events and 19 died, while 79 were disease free. Five- and 10-year event-free survival (EFS) were 73 and 70 %, and overall survival (OS) was 81 and 74 %, respectively. MYCN status was significant for EFS, but not for OS in multivariate analysis. The survival rates of patients who complied with all the inclusion criteria for INES trials are higher compared to those that included also not registered patients. Five-year EFS and OS for INES 99.2 were 87.8 and 95.7 %, while our stage 4s population obtained 78 and 87 %. Concerning 99.3, 5-year EFS and OS were 86.7 and 95.6 %, while for stage 4 we registered 61 and 68 %. MYCN amplification had a strong impact on prognosis and therefore we consider it unacceptable that many patients were not studied for MYCN and probably inadequately treated. Ten-year survival rates were shown to decrease: EFS from 73 to 70 % and OS from 81 to 74 %, indicating a risk of late events, particularly in stage 4s. Population-based registries like European ENCCA WP 11-task 11 will possibly clarify these data.

Datos de la publicación

ISSN/ISSNe:: 1699-048X, 1699-3055
Tipo:: Article
Páginas:: 76-83
DOI:: 10.1007/s12094-016-1505-1
Factor de Impacto:: 0,819 SCImago ℠
Cuartil:: Q2 SCImago ℠

Documentos

No hay documentos

Métricas

Filiaciones

Di Cataldo, A:: Univ Catania, Hosp Policlin, Dept Clin & Expt Med, Unit Paediat Haematol & Oncol, Via Santa Sofia 78, I-95123 Catania, Italy
Agodi, A:: Univ Catania, Dept GF Ingrassia, Via Santa Sofia 87, I-95123 Catania, Italy
Balaguer, J:: Hosp Univ & Politecn La Fe, Unidad Oncol Pediat, Ave Fernando Abril Martorell 106, Valencia 46026, Spain
Garaventa, A:: Giannina Gaslini Childrens Hosp, Paediat Haematol Oncol Dept, I-16148 Genoa, Italy
Barchitta, M:: Univ Catania, Dept GF Ingrassia, Via Santa Sofia 87, I-95123 Catania, Italy
Segura, V:: Hosp Univ & Politecn La Fe, Unidad Oncol Pediat, Ave Fernando Abril Martorell 106, Valencia 46026, Spain
Bianchi, M:: Regina Margherita Hosp, Piazza Polonia 94, I-10126 Turin, Italy
Castel, V:: Hosp Univ & Politecn La Fe, Unidad Oncol Pediat, Ave Fernando Abril Martorell 106, Valencia 46026, Spain
Castellano, A:: Bambino Gesu Pediat Hosp, IRCCS, Dept Paediat Haematol Oncol, Rome, Italy
Cesaro, S:: Osped Borgo Roma, Paediat Haematol Oncol, Piazzale LA Scuro 10, I-37134 Verona, Italy
Couselo, JM:: Hosp Clin Univ Santiago, Pediat Oncol, Travesia de Choupana S-N, Santiago De Compostela 15706, Spain
Cruz, O:: Hosp San Joande Deu, Pediat Oncol, Passeig St Joan de Deu 2, Barcelona 08950, Spain
D'Angelo, P:: Civ & Benfratelli Hosp, Paediat Haematol Oncol, Piazza Nicola Leotta 4, Palermo, Italy
De Bernardi, B:: Giannina Gaslini Childrens Hosp, Paediat Haematol Oncol Dept, I-16148 Genoa, Italy
Donat, J:: Hosp Clin Valencia, Pediat Oncol, Ave Blasco Ibanez 17, Valencia 46010, Spain
de Andoin, NG:: Hosp Univ Donostia, Pediat Oncol, Doctor Begiristain Kalea 117, Donostia San Sebastian 20080, Spain
Hernandez, MI:: Hosp Univ Son Espases, Pediat Oncol, Ctra Valldemossa 79, Palma De Mallorca 07010, Spain
La Spina, M:: Univ Catania, Hosp Policlin, Dept Clin & Expt Med, Unit Paediat Haematol & Oncol, Via Santa Sofia 78, I-95123 Catania, Italy
Lillo, M:: Hosp Gen Univ Albacete, Pediat Oncol, Calle Hermanos Falco 37, Albacete 02006, Spain
Lopez-Almaraz, R:: Hosp Univ Canarias, Pediat Oncol, Carretera Ofra S-N, San Cristobal La Laguna, Santa Cruz De T, Spain
Luksch, R:: Fdn IRCCS Ist Nazl Tumori, Paediat Oncol Unit, Via Venezian 1, Milan, Italy
Mastrangelo, S:: Policlin Gemelli, Paediat Haematol Oncol, Via Pineta Sacchetti, Rome, Italy
Mateos, E:: Hosp Univ Reina Sofia, Pediat Oncol, Ave Menendez Pidal S-N, Cordoba 14004, Spain
Molina, J:: Hosp Virgen Del Camino, Pediat Oncol, C De Irunlarrea 4, Pamplona 31008, Spain
Moscheo, C:: Fdn IRCCS Ist Nazl Tumori, Paediat Oncol Unit, Via Venezian 1, Milan, Italy
Mura, R:: Osped Microcitem, Paediat Haematol Oncol, Cagliari, Italy
Porta, F:: Spedali Civil Brescia, Paediat Haematol Oncol, Piazzale Spedali Civili 1, I-25123 Brescia, Italy
Russo, G:: Univ Catania, Hosp Policlin, Dept Clin & Expt Med, Unit Paediat Haematol & Oncol, Via Santa Sofia 78, I-95123 Catania, Italy
Tondo, A:: Meyer Hosp, Paediat Haematol Oncol, Via Luca Giordano 13, I-50132 Florence, Italy
Torrent, M:: Hosp Santa Creui St Pau, Paediat Oncol, Carrer St Quinti 89, Barcelona 08026, Spain
Vetrella, S:: Santobono Pausilipon Hosp, Paediat Haematol Oncol, Via Posillipo 226, I-80123 Naples, Italy
Villegas, JA:: Hosp Univ Cent Asturias, Pediat Oncol, Ave Roma S-N, Oviedo 33011, Asturias, Spain
Viscardi, E:: Padova Hosp, Paediat Haematol Oncol, Via Giustiniani 3, I-35128 Padua, Italy
Zanazzo, GA:: Burlo Garofolo Hosp, Paediat Haematol Oncol, Via Istria 65, I-34137 Trieste, Italy
Canete, A:: Hosp Univ & Politecn La Fe, Unidad Oncol Pediat, Ave Fernando Abril Martorell 106, Valencia 46026, Spain